Phase I/II Trial of Sequential Chemoradiotherapy Using a Novel Hypoxic Cell Radiosensitizer, Doranidazole (PR-350), in Patients With Locally Advanced Non-Small-Cell Lung Cancer (WJTOG-0002)

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 3, 2007, Pages 786-792

  Nishimura, Yasumasa ^a   Nakagawa, Kazuhiko ^a   Takeda, Koji ^b   Tanaka, Masahiro ^b   Segawa, Yoshihiko ^c   Tsujino, Kayoko ^d   Negoro, Shunichi ^d   Fuwa, Nobukazu ^e   Hida, Toyoaki ^e   Kawahara, Masaaki ^f   Katakami, Nobuyuki ^g   Hirokawa, Keiko ^g   Yamamoto, Nobuyuki ^h   Fukuoka, Masahiro ^a   Ariyoshi, Yutaka ⁱ  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f Kinki Central Hospital   (Japan)

^g KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ Marumo Hospital   (Japan)

Author keywords

Chemoradiation; Clinical trial; Hypoxic cell radiosensitizer, Doranidazole; Non small cell lung cancer

Indexed keywords

CHEMORADIATION; DORANIDAZOLE; HYPOXIC CELL RADIOSENSITIZERS; LUNG CANCER; SEQUENTIAL CHEMORADIOTHERAPY;

CHEMOTHERAPY; DOSIMETRY; ONCOLOGY; TOXICITY; TUMORS;

RADIOTHERAPY;

CARBOPLATIN; CISPLATIN; DORANIDAZOLE; PACLITAXEL; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRONCHOSCOPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HYPOXIC CELL; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIATION PNEUMONIA; SURVIVAL RATE; SURVIVAL TIME; THORAX RADIOGRAPHY;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; RADIATION PNEUMONITIS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 34548672366     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.04.008     Document Type: Article

References (23)

1. Pritchard R.S., and Anthony S.P. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 125 (1996) 723-729
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 (1995) 899-909
3. Chevalier T.L., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83 (1991) 417-423
4. Nishimura Y. Rationale for chemoradiotherapy. Int J Clin Oncol 9 (2004) 414-420
5. Rowell N.P., and O'Rourke N.P. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 4 (2004) CD002140
6. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
7. Fournel P., Robinet G., Thomas P., et al. Randomized Phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23 (2005) 5910-5917
8. Tannock I.F. Treatment of cancer with radiation and drugs. J Clin Oncol 14 (1996) 3156-3174
9. Hall E.J., and Giaccia A.J. Oxygen effect and reoxygenation. In: Hall E.J., and Giaccia A.J. (Eds). Radiobiology for the Radiologist. 6th ed. (2006), Lippincott Williams & Wilkins, St. Philadelphia 85-105
10. Hall E.J., and Giaccia A.J. Radiosensitizers and bioreductive drugs. In: Hall E.J., and Giaccia A.J. (Eds). Radiobiology for the Radiologist. 6th ed. (2006), Lippincott Williams & Wilkins, St. Philadelphia 419-431
11. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6 (1994) 509-518
12. Kaanders J.H., Bussink J., and van der Kogel A.J. . Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 14 (2004) 233-240
13. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind Phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46 (1998) 135-146
14. Oya N., Shibamoto Y., Sasai K., et al. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): Radiosensitization efficiency and toxicity. Int J Radiat Oncol Biol Phys 33 (1995) 119-127
15. Suzuki Y., Hasegawa M., Hayakawa K., et al. In vivo study of radiosensitizing effect of hypoxic cell radiosensitizer PR-350 on a human small cell lung cancer. Anticancer Res 19 (1999) 3993-4000
16. Shibamoto Y., Kubota T., Kishii K., and Tsujitani M. Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole. Radiother Oncol 56 (2000) 265-270
17. Matsuoka H., Shibamoto Y., Kubota T., et al. In vivo efficacy and pharmacokinetics of a new hypoxic cell radiosensitizer doranidazole in SUIT-2 human pancreatic cancer xenografted in mouse pancreas. Oncol Rep 7 (2000) 23-26
18. Nemoto K., Shibamoto Y., Ohmagari J., et al. Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy. Anticancer Drugs 12 (2001) 1-6
19. Sunamura M., Karasawa K., Okamoto A., et al. Phase III trial of radiosensitizer PR-350 combined with intraoperative radiotherapy for the treatment of locally advanced pancreatic cancer. Pancreas 28 (2004) 330-334
20. Inoue A., Kunitoh H., Sekine I., et al. Radiation pneumonitis in lung cancer patients: A retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys 49 (2001) 649-655
21. Eschwege F., Sancho-Garnier H., Chassagne D., et al. Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. Int J Radiat Oncol Biol Phys 39 (1997) 275-281
22. Riese N.E., Buswell L., Noll L., et al. Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 Phase III head and neck trial. Int J Radiat Oncol Biol Phys 39 (1997) 855-858
23. Choy H., Nabid A., Stea B., et al. Phase II multicenter study of induction chemotherapy followed by concurrent faproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5918-5928